| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2873750 | The Annals of Thoracic Surgery | 2015 | 9 Pages |
Abstract
Methylated DLX4 is a potential biomarker that predicts poor prognosis after curative resection of pathologic stage I NSCLC. Identification of patients with methylated DLX4 may assist stratification for appropriate adjuvant treatment strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Hiroaki MD, PhD, Kazuaki MD, PhD, Yoshinori MD, PhD, Kiyomi MD, PhD, Hideki MD, PhD, Morihito MD, PhD,